Clinical Trials Logo

Human Papilloma Virus Infection clinical trials

View clinical trials related to Human Papilloma Virus Infection.

Filter by:

NCT ID: NCT03677960 Not yet recruiting - HIV Infection Clinical Trials

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

Start date: December 8, 2018
Phase: Phase 1
Study type: Interventional

This study evaluates the use of ABI-1968, a topical cream, in the treatment of anal precancerous lesions in adults with and without human immunodeficiency virus (HIV) infection

NCT ID: NCT03542227 Active, not recruiting - Clinical trials for Human Papilloma Virus Infection

Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine

ABSOP-FollowUp
Start date: December 11, 2017
Phase:
Study type: Observational

The aim of the study is to develop robust analytical protocols for first-void urine sample preparation and antibody assays to monitor vaccine induced immunity against HPV (Human Papillomavirus).

NCT ID: NCT03202992 Active, not recruiting - HIV Infection Clinical Trials

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

Start date: August 11, 2017
Phase: Phase 1
Study type: Interventional

This study evaluates the use of ABI-1968, a topical cream, in the treatment of anal precancerous lesions in adults with and without human immunodeficiency virus (HIV) infection.

NCT ID: NCT02811367 Completed - Clinical trials for Human Papilloma Virus Infection

The HPV Self-test as a Test of Cure in Madagascar

Start date: June 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to find out whether Self-HPV may be an accurate method for the follow-up of women with a history of HPV infection.

NCT ID: NCT02714114 Completed - Clinical trials for Human Papilloma Virus Infection

Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine (AB-SOP Study)

AB-SOP
Start date: September 2015
Phase: N/A
Study type: Observational

The aim of the study is to develop robust analytical protocols for first-void urine sample preparation and antibody assays to monitor natural and/or vaccine induced immunity against HPV (Human Papillomavirus).

NCT ID: NCT02634190 Active, not recruiting - Clinical trials for Human Papilloma Virus Infection

Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HC2® Test Using LBC ThinPrep® Specimens

Start date: June 2009
Phase:
Study type: Observational

To assess and compare the performance of the HR HPV HC2® test (Qiagen/Digene) and the APTIMA® HPV Assay (Hologic) using LBC Specimens (ThinPrep® Pap Test) for the detection of HPV infection and high-grade CIN lesions in a screening population of women 30 years of age or older in Germany.

NCT ID: NCT02258659 Active, not recruiting - Clinical trials for Stage III Squamous Cell Carcinoma of the Oropharynx

Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer

OPTIMA
Start date: September 22, 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating patients with stage III or IV human papillomavirus (HPV)-related oropharyngeal cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, hydroxyurea, fluorouracil, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them spreading. Radiation therapy uses high energy x rays to kill tumor cells. Giving nab-paclitaxel and carboplatin before chemoradiation may make the tumor smaller and reduce the amount of chemotherapy and radiation therapy needed. Assigning chemotherapy and radiation therapy based on response (response-based therapy) and giving patients who are responding well lower doses of treatment may help reduce the occurrence of side effects.

NCT ID: NCT02135419 Recruiting - HIV Infection Clinical Trials

Topical or Ablative Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Squamous Intraepithelial Lesions

ANCHOR
Start date: September 24, 2014
Phase: Phase 3
Study type: Interventional

This randomized phase III trial compares topical or ablative treatment with active monitoring in preventing anal cancer in patients with human immunodeficiency virus (HIV) and high-grade squamous intraepithelial lesions (HSIL). Anal HSIL is tissue in the anal canal that has been damaged by infection with human papillomavirus (HPV) and is at risk for turning into anal cancer. It is not yet known if treating HSIL is more effective than active monitoring in preventing patients from developing anal cancer.

NCT ID: NCT02124252 Recruiting - Clinical trials for Human Papilloma Virus Infection

Community-Driven Cervical Cancer Prevention in Western Kenya

Start date: January 2016
Phase: N/A
Study type: Interventional

There are many challenges to implementation of cervical cancer prevention in resource-limited countries, despite evidence based screening and treatment strategies. The investigators hypothesize that self-collected HPV specimens offered in a community health campaign setting will

NCT ID: NCT02067507 Enrolling by invitation - Clinical trials for Human Papilloma Virus Infection

Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County

Start date: June 2012
Phase: N/A
Study type: Interventional

The primary aim of the project is to increase human papillomavirus (HPV) vaccine receipt rates among low-income, ethnic minority adolescents (girls and boys 11-17 years of age) in Los Angeles County. We will accomplish this goal by implementing and rigorously evaluating interventions in multiple venues that serve our target population, including the Los Angeles County Department of Public Health (LACDPH) and two large Federally Qualified Health Centers (FQHCs). Our hypotheses are: Primary hypothesis: 1. The intervention group will have a higher rate of HPV vaccine initiation at follow-up compared to the control group. Secondary hypothesis: 2. The intervention group will have higher vaccine completion rates (3 doses) at follow-up compared to the control group.